University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
NCT Number: NCT00761618
The goal of this clinical research study is to learn if draining the IPC every day is better at than draining it 3 times a week.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Interventional
Phase 2
Houston, Texas, 77030, United States
An IPC is a silicone (rubberlike) tube that is inserted into the chest cavity to drain excess fluid that is in your chest. At MD Anderson, patients are told to drain their IPC every day. At other institutions, patients are told to drain their IPC less often.
Before IPC Placement:
Before you can have the IPC inserted, the following tests and procedures will be performed to help the doctor decide if you need to have an IPC inserted:
IPC placement:
You will have an IPC placed to drain the fluid in your chest cavity. You will be given a separate consent for to sign for this procedure and your doctor will give you detailed instructions regarding the procedure itself.
Study Groups:
A chest x-ray will be performed right after the IPC placement. You will be randomly assigned (as in the flip of a coin) to 1 of 2 groups, after your chest x-ray or the following day when you return to clinic for follow up. Group 1 will have their IPC drained every day, and Group 2 will have their IPC drained 3 times a week (Monday, Wednesday, and Friday or Tuesday, Thursday, and Saturday). You will be given detailed instructions on when and how to drain your catheter.
Follow-Up Visits:
Two (2) weeks after you receive the IPC, you will return to the clinic for a follow-up visit so the doctor can check your IPC for possible leaking, infection, and see how much pleural fluid has drained. After the follow-up visit at 2 weeks, you will come into the clinic every 4 weeks until your IPC is removed. During each follow-up visit the following tests and procedures will be performed to see how your condition has changed:
After the IPC is removed, at 3 and 6 months, you will have follow-up visits at M. D. Anderson or at your local doctor's office. At these visits you will have chest x-rays to see if the pleural fluid has come back or not.
The study personnel will contact you by phone, email or mail periodically during the study and at 3 months and 6 months after the IPC has been removed to check on your status. The phone calls, email, or mail follow-up will take about 5-10 minutes to complete. You will be asked how you are doing and if you have any questions or concerns that you may want to discuss with the your doctor. You will also be asked if you have had a chest x-ray since being off study. If you have had an x-ray, you will be asked to share the results with the study doctor.
This is an investigational study.
Up to 250 patients will take part in this study. All will be enrolled at MD Anderson.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
IPC drained daily (Group 1) or 3 times per week (Group 2)
IPC placed in chest cavity to drain excess fluid
Other names: Indwelling Pleural Catheter
Chest X-Rays at 3 and 6 month follow up visits
Time frame: 2 weeks after intrapleural catheter placement
Time to pleurodesis (TTP), defined as the time from catheter insertion to catheter removal.
M.D. Anderson Cancer Center
Other
Effectiveness of Daily Versus Three Times a Week Drainage After Placement of Intrapleural Catheters for the Palliative Management of Pleural Effusions Associated With Malignancies
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05891171
Adenocarcinoma, Adnexal Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT02711553
Advanced Cancer, Biliary Tract Cancer
Tucson, Arizona, United States
View Trial DetailsNCT01087554
Advanced Cancer
Houston, Texas, United States
View Trial DetailsNCT04435444
Advanced Cancer
New York, United States
View Trial Details